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Abstract
Background. Increased arterial stiffness assessed by pulse wave velocity (PWV) measurement is a marker of arterial 
wall dysfunction and has an independent predictive value for adverse cardiovascular outcomes. A positive correlation 
between the neutrophil-to-lymphocyte ratio (NLR) and PWV has been reported in chronic inflammatory conditions 
and the general population as well.
Furthermore, an association between NLR and PWV has been assumed in hypertensive patients. However, the 
available data are scarce.
The objective of the study was to validate the association between NLR and PWV in a homogenous group of 
controlled-hypertensive patients without chronic inflammatory conditions. 
Material and methods. A retrospective observational study was conducted in outpatient cardiology and a general 
practice. A total number of 25 already on-target treated essential hypertensive, non-diabetic and non-chronic kidney 
disease (non-CKD) patients were selected. PWV was automatically calculated for each patient using the ABPM 
BPLab® device. The following laboratory data were collected: complete blood count, fibrinogen, alkaline phos-
phatase, lactate dehydrogenase, uric acid, serum glucose, total cholesterol, triglycerides, iron, calcium, and creatinine. 
Neutrophil-to-lymphocyte ratio was calculated. Antihypertensive treatment classes were also assessed.
Results. A correlation between increased NLR and PWV in a homogenous group of controlled-hypertensive patients 
was identified.
Conclusions. There is an evident relation between increased NLR and increased PWV in controlled hypertensive 
patients without evidence of chronic inflammatory conditions.
Key words: neutrophil-to-lymphocyte ratio; pulse wave velocity; hypertension
Arterial Hypertens. 2020, vol. 24, no. 2, pages: 67–73
DOI: 10.5603/AH.a2020.0008
arterial hypertension 2020, vol. 24, no. 2
68 www.ah.viamedica.pl
Introduction
The leading cause of morbidity and mortality world-
wide is represented by cardiovascular diseases (CVD); 
hypertension is considered a major risk factor for 
heart disease, being ranked the third most common 
cause leading to disability in the world [1].
Arterial stiffness is characterized by degeneration 
of extracellular matrix in the media layer of elastic 
arteries with loss of elastic fibres, and increased fi-
brosis as a consequence of increased cyclic stress 
[2]. The changes in arterial stiffening are morpho-
logically different from atherosclerosis, a process that 
involves the intima layer and is characterized by 
patchy intimal thickening with subsequent lumen 
narrowing [3].
Increased arterial stiffness is considered to be the 
initial indicator of arterial wall dysfunction and has 
an independent predictive value for adverse CV out-
comes, along with traditional CV risk factors [4–6]. 
Patients with diabetes mellitus, metabolic syndrome, 
or chronic inflammation status are at high risk of 
developing increased arterial stiffness [7, 8].
Pulse wave velocity (PWV) is the most commonly 
used method for arterial stiffness assessment [9].
As arterial stiffening affects mainly the proximal 
arteries, the stiffness gradient between proximal and 
distal arteries will subside leading to decreased wave 
reflection from the resistance vessels, and conse-
quently increased pressure in the microcirculation, 
with negative effects on the perfused organs, particu-
larly brain and kidney [10].
Additionally, a reduced arterial filling capacity as 
a consequence of increased stiffness leads to an en-
hanced pulse pressure (PP) and causes prematurely 
recoil of the reflected waves with a consequent en-
hancement of late systolic pressure and gradual left 
ventricular hypertrophy development [11, 12].
Although PWV is indisputably an excellent tool 
for CV risk stratification, it also bears relevant limita-
tions [13]. Pulse wave velocity is influenced by many 
clinical factors like age, blood pressure (BP) and 
other traditional CV risk factors [14]. For proper 
evaluation, target BP control should be achieved 
before PWV determination [9].
As a result of the age-related reduction in nitric 
oxide synthesis and increased vasoconstrictor avail-
ability, elder individuals present impairment in vas-
cular function leading to decreased resistance to oxi-
dative stress and changes in vascular structure with 
wall thickening and increased stiffness in conduit 
arteries [15–17]. Consequently, the function of pre-
serving a constant BP against a pulsating blood flow 
is more impaired in elderly individuals.
For PWV assessment, invasive and non-invasive 
methods are accessible, non-invasive methods being 
currently available in clinical practice. Arterial stiffness 
can be determined by non-invasive carotid-femoral 
PWV computation using a tonometry device [14, 15].
Pulse wave velocity cut-off values vary among dif-
ferent populations as a consequence of the many con-
founders. In middle-aged patients with hypertension, 
a PWV value higher than 10m/s is associated with 
significant aortic function deterioration [15, 18].
Ambulatory 24-hour PWV analysis is a validated 
arterial stiffness measurement that also involves assess-
ment of central arterial pressure (CAP) and augmen-
tation index (AIx) calculations, both being able to be 
estimated from the common carotid artery or a pe-
ripheral artery (i.e. brachial artery) waveform [19–21].
The neutrophil-to-lymphocyte ratio (NLR) is 
currently investigated as an inflammatory marker. 
NLR is associated with atherosclerosis, hypertension, 
coronary artery disease, acute coronary syndromes 
and other known inflammatory conditions; addi-
tionally, NLR may be an indicator of disease severity 
of coronary artery disease and calcific atherosclerosis 
[23–27].
A positive correlation between NLR and PWV in 
the general population has been reported in previ-
ous studies, but also in research focused on chronic 
inflammatory conditions [28–30]. Furthermore, an 
association between PWV and NLR in hypertensive 
patients identified NLR as a valid index for arterial 
stiffness [31]. Nevertheless, a relationship between 
NLR and arteriosclerosis in hypertensive patients 
is scarce. 
The premise of our study was to validate the as-
sociation between NLR and arterial stiffness assessed 
by PWV in a homogenous group of controlled-hy-
pertensive patients.
Material and methods
A retrospective observational study was conducted 
in outpatient cardiology and a general practice. Data 
were collected after the study protocol approval by 
local Ethics Committee no. 1172/14/01/2019. All 
the subjects afforded written informed consent.
A total number of fifty-nine unselected, already 
treated at target essential hypertensive adult patients 
underwent a 24-hour ambulatory blood pressure 
monitoring (ABPM) evaluation from June 2016 to 
June 2017, using a BPLab® device (BPLab® GmbH, 
Schwalbach am Taunus, Germany); derived used pa-
rameters were: mean arterial pressure (MAP) and 
pulse wave velocity (PWV).
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Subjects with any of the following concomitant 
diagnosis: atrial fibrillation, frequent ectopic beats, 
secondary hypertension, documented or suspected 
cardiomyopathy, chronic inflammatory conditions, 
infectious diseases, or malignant tumours were ex-
cluded from statistical analysis. In addition, we did 
not include in our research patients with antihyper-
tensive regimens containing amlodipine or valsartan. 
Patients were instructed to avoid alcohol, caffeine-
containing products and substantial meal 8 hours 
before and during 24-hour monitoring.
The 24-hour BP reports along with the laboratory 
tests performed within the monitoring time frame, 
anthropometric and demographic data were retrospec-
tively collected from an integrated electronic database.
The carotid-femoral PWV was automatically cal-
culated using the ABPM BPLab® device, which is 
an automatic, validated device to measure the time 
delay between the rapid upstroke of the feet of simul-
taneously recorded pulse waves in the carotid and the 
femoral arteries, over a 24 hours period [32]. The 
“surrogate” length of the aorta was measured non-
invasively with a non-elastic tape measure, between 
carotid and femoral artery. In order to reduce varia-
tions in the measurements, one trained technician 
performed PWV data collection. 
With respect to the inclusion and exclusion criteria, 
a total number of 25 already treated at target essential 
hypertensive, non-diabetic and non-CKD patients were 
included in the study. Out of these patients, seventeen 
were males (68.0%) and eight were females (32.0%). 
The following laboratory data were collected: 
complete blood count, fibrinogen, alkaline phos-
phatase, lactate dehydrogenase, uric acid, serum glu-
cose, total cholesterol, triglycerides, iron, calcium, 
and creatinine. Neutrophil-to-lymphocyte ratio was 
calculated. Glomerular filtration rate was estimated 
using the CKD-EPI formula. Antihypertensive treat-
ment classes were also assessed. 
The association between the qualitative variables 
was assessed using the Student’s t-test. P values 
< 0.05 were considered statistically significant, and 
all confidence intervals are 95%. Linear regression 
analysis was performed in order to test the relation-
ship between selected parameters, Pearson product-
moment correlation coefficient (r) was used to as-
sess the strength of the association. The statistical 
analysis was performed using SPSS 22.0 (IBM Corp. 
Released 2013. IBM SPSS Statistics for Windows, 
Version 22.0. Armonk, USA), and Graph Pad Prism 
8.1.2 (227) software (GraphPad Software Inc., San 
Diego, USA).
Results
The mean age of our study group (25 patients) was 
54.96 ± 13.03 (range 29–87) years old; mean age in 
the male subgroup was 53.45 ± 14.59 years old and 
mean age in the female subgroup was 55.68 ± 14.6 
years old, respectively. Subject’s body mass index 
(BMI) was 29.77 ± 4.10 kg/m2 (range 20.50–35.50 
kg). Overweight was diagnosed in 45% of the study 
subjects, 45% have obesity grade I and 5% obesity 
grade II. Distinctive laboratory descriptive data and 
their correlation to PWV are depicted in Table 1.
Table 1. Laboratory descriptive data and their correlation to pulse wave velocity (PWV)
Parameters N Min Max Range
PWV
p value Pearson’s r
Neutrophils (NV: 1.5–7.5 × 103/μL) 25 2.46 8.45 5.99 –
Lymphocytes (NV: 1.0–4.0 × 103/μL) 25 0.82 4.00 3.18 –
NLR 25 9.10 15.70 6.60 –
Fibrinogen (NV: 1.5–4.0 g/L) 12 2.40 5.50 3.10 0.04 0.58
Alkaline phosphatase (NV: 100–300 U/L) 21 57.00 352.00 295.00 0.32 0.22
Lactate dehydrogenase (NV: 240–480 U/L) 18 149.00 440.00 291.00 0.97 –0.01
Uric acid (NV: 200–400 U/L) 23 173.30 749.00 575.70 0.11 0.33
Serum glucose (NV: 4–5.4 mmol/L) 25 4.41 9.99 5.58 0.01 0.57
Total cholesterol (NV: 2.8–5.2 mmol/L) 25 3.15 8.48 5.33 0.97 0.01
Triglyceride (NV: 0.55–1.90 mmol/L) 22 0.61 10.60 9.99 0.41 0.03
Iron (NV: 9.0–30.4 μmol/L) 15 9.20 23.30 14.10 0.63 0.13
Total calcium (NV: 2.15–2.57 mmol/L) 16 1.94 2.53 0.59 0.75 0.08
N — number of patients; Min — minimum; Max — maximum; NV — normal values; NLR — neutrophil-to-lymphocyte ratio
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Results outlined in Table 1 demonstrates a positive 
correlation between fibrinogen and PWV (p = 0.04, 
Pearson’s r = 0.58) and between serum glucose and 
PWV (p = 0.01, Pearson’s r = 0.57).
Pulse wave velocity (m/s) was analysed by gender 
distribution as presented in Figure 1; within the two 
subgroups, no statistically significant difference was 
identified (p = 0.46).
Age and ABPM BPLab® derived data (MAP, PWV) 
correlated to neutrophil-to-lymphocyte ratio were 
analysed, as presented in Table 2.
A correlation between PWV and NLR (p < 0.01) 
was found in our statistical analysis. We could not 
identify a statistically significant correlation between 
NLR and MAP, although there is a positive correla-
tion (p = 0.48) (see Tab. 2).
In the interest of analysing the impact of dis-
ease duration and age-dependent NLR on PWV, 
the study population was divided according to age 
(≥ 50 years and ≥ 60 years). Analysis of Pearson’s 
correlation test regarding the association between 
age and age-dependent NLR to PWV is presented 
in Table 3.
Regarding age-dependent NLR, for subjects in age 
groups 50 years and older, we identified a correlation 
between NLR and PWV as is illustrated in Table 3 
(p = 0.01, Pearson’s r = 0.71). For subjects in the age 
group 60 years and older, we identified a correlation 
between NLR and PWV as seen in Table 3 (p = 0.01, 
Pearson’s r = 0.85).
Table 2. Neutrophil-to-lymphocyte (NLR) ratio correlation to 24-hour ambulatory blood pressure monitoring (ABPM) derived data, and age 
in the studied group
Parameters NLR MAP PWV Age
NLR
Pearson’s r 1 0.15 0.65 0.37
p value – 0.48 0.00 0.07
MAP
Pearson’s r 0.15 1 0.51 –0.02
p value 0.48 – 0.01 0.94
PWV 
Pearson’s r 0.65 0.51 1 0.36
p value 0.00 0.01 – 0.08
Age
Pearson’s r 0.37 –0.02 0.36 1
p value 0.07 0.94 0.08 –
MAP — mean arterial pressure; PWV — pulse wave velocity
Table 3. Pulse wave velocity (PWV) correlation to age and neutrophil-to-lymphocyte (NLR) in studied subjects
Parameters
PWV
p 95% CI Pearson’s r N
Age ≥ 50 0.09 –0.07 to 0.73 –0.40 18
Age ≥ 60 0.55 –0.51 to 0.77 0.22 9
NLR for age ≥ 50 0.01 0.36 to 0.88 0.71 18
NLR for age ≥ 60 0.01 0.45 to 0.96 0.85 9
CI — confidence interval; N — number of patients
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Discussions
The neutrophil-to-lymphocyte ratio is a simple, read-
ily available, inexpensive marker of inflammation 
and is expected to be a marker of oxidative stress as 
well. A relation between NLR and hypertension has 
been reported in previous studies, as increased NLR 
in elderly hypertensive patients was associated with 
increased all-cause mortality [33]. Moreover, NLR 
was raised in prevalent hypertensive patients and also 
in individuals with incident hypertension [34, 35].
Even though NLR is a reliable marker of inflam-
mation, it should be considered that NLR levels 
may be influenced by different situations such as 
hydration fluctuation [36]. Furthermore, when in-
terpreting different study results concerning NLR 
values, antihypertensive drugs should be considered, 
as amlodipine and valsartan administration may de-
crease NLR [24]. Because use of valsartan reduced 
interleukin 6 and tumour necrosis factor a in hy-
pertensive patients in previous studies and valsartan 
and amlodipine as well were reported to decrease 
oxidative stress and inflammatory response [24], we 
believe that patients benefiting from these antihy-
pertensive regimens will experience reduced NLR 
values in comparison with patients treated with other 
antihypertensive regiments, thus preventing us from 
properly assessing the correlation between NLR and 
PWV.
Neutrophil-to-lymphocyte ratio is also an accurate 
marker for the atherosclerotic disease, which might 
be related to the influence of the autonomic nervous 
system as lymphocytes present cholinergic recep-
tors while granulocytes expose adrenergic receptors. 
Sympathetic nervous system stimulation can increase 
granulocytes number, and parasympathetic nervous 
system stimulation can increase lymphocytes [37]. 
Consequently, vessel sympathetic overactivation, 
which is encountered in hypertension, heart failure, 
acute coronary syndromes and arrhythmias, can lead 
to increased neutrophils and endothelial dysfunc-
tion, an essential step in atherosclerotic plaque de-
velopment [38]. Furthermore, central and peripheral 
artery stiffness are reported as enhanced under the 
influence of increased muscle sympathetic nerve ac-
tivity, which leads to the reasonable assumption that 
sympathetic hyperactivity might be a contributing 
factor to the association between increased NLR and 
PWV [39].
The correlation between NLR and arterial stiff-
ness has been reported in multiple previous studies, 
particularly in individuals diagnosed with chronic 
inflammatory conditions. Statistically significant 
associations were found in patients with systemic 
lupus erythematosus, a pathology long known to 
bare important traditional and non-traditional CV 
risk factors, and also in patients with inflammatory 
bowel disease, a pathology with a low prevalence of 
traditional CV risk factors [30, 40].
There are few studies investigating a relation be-
tween NLR and PWV that included individuals 
without a significant inflammatory condition. Ad-
ditionally, records aiming to identify an association 
between PWV and NLR in hypertensive patients are 
limited as well. Nevertheless, there are data describ-
ing NLR as a valid indicator for arterial stiffness in 
hypertensive patients [41].
Our study identified a statistically significant 
association between NLR and arterial stiffness as-
sessed by PWV analysis in a homogenous group 
of hypertensive patients. Furthermore, we identified 
a positive correlation between fibrinogen and PWV 
as well. Even though a relation between NLR and 
arterial stiffness in hypertensive patients has been re-
ported before, the novelty of our study consists in the 
homogenous population included, with controlled 
hypertension and lacking in confounding factors for 
NLR. Patients with confounding factors for PWV 
such as atrial fibrillation, frequent ectopic beats, 
secondary hypertension, documented or suspected 
cardiomyopathy were excluded in order to assess a re-
lationship between PWV and NLR accurately. For 
the same purpose, patients with inflammatory condi-
tions (diabetes, CKD, infectious diseases, malignant 
tumours, other chronic inflammatory conditions) 
already known to present increased NLR and a high 
risk for increased PWV were also excluded.
In patients aged 60 and older, hypertension is the 
most frequent cardiovascular condition. For proper 
evaluation of the influence on PWV of disease-du-
ration-dependent hypertension, we further divided 
our study group according to age as follows: patients 
≥ 50 years and patients ≥ 60 years. Ageing, which 
we assume is associated with prolonged hypertensive 
disease duration, did not have a statistically signifi-
cant correlation to PWV, most likely due to the small 
sample group. As expected, aged-dependent NLR 
was associated with PWV in each age group.
Impaired glucose tolerance stimulates non-enzy-
matic glycation and cross-linking of collagen, thus 
contributing to increased arterial stiffness [42]. Glu-
cose serum levels also proved to be correlated to 
PWV in our study population. We included non-
diabetic patients, with incidental low-level hypergly-
caemia recorded in a small number of individuals; 
hence we believe the positive correlation between 
glycaemia and PWV may be casual in our subjects, 
mainly as a result of small sample size.
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Our research has several inherent limitations. 
First, our study was a retrospective observational one 
which included a cluster of patients from the urban 
area, highly adherent to antihypertensive treatment, 
which may have different characteristics from the 
general hypertensive population. We did not include 
confounding factors (i.e. regional anthropometric in-
dices) that could influence our results. Second, PWV 
was not determined prior to BP optimal control. In 
addition, the sample size of our research work was 
limited due to recent relative availability to use the 
BPLab® device, which may contribute to the results.
Conclusion
There is an evident relation between increased neu-
trophil-to-lymphocyte ratio and increased pulse wave 
velocity in controlled hypertensive patients with no 
confirmation of chronic inflammatory conditions. 
Further directed investigations are required through 
prospective studies.
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